Targeted treatment of vitiligo currently relies on the small molecule JAK1/2 inhibitor ruxolitinib (Opzelura) or off-label use of tofacitinib (a small molecule JAK1/3 inhibitor). This evidence concerns the gene JAK1 and vitiligo.